The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...
Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...
The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results